Regulatory agencies have a key role in facilitating the development of new drugs for Alzheimer disease, particularly given the challenges associated with early intervention. Here, we highlight the strategies of the European Medicines Agency to help address such challenges.
The European Medicines Agency's strategies to meet the challenges of Alzheimer disease / Haas, M.; Mantua, V.; Haberkamp, M.; Pani, L.; Isaac, M.; Butlen-Ducuing, F.; Vamvakas, S.; Broich, K.. - In: NATURE REVIEWS DRUG DISCOVERY. - ISSN 1474-1776. - 14:4(2015), pp. 221-222. [10.1038/nrd4585]
The European Medicines Agency's strategies to meet the challenges of Alzheimer disease
Pani L.;
2015
Abstract
Regulatory agencies have a key role in facilitating the development of new drugs for Alzheimer disease, particularly given the challenges associated with early intervention. Here, we highlight the strategies of the European Medicines Agency to help address such challenges.
| File | Dimensione | Formato | |
|---|---|---|---|
|
nrd4585.pdf
Accesso riservato
Tipologia:
Versione pubblicata dall'editore
Dimensione
167.33 kB
Formato
Adobe PDF
|
167.33 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
